Heron Therapeutics
HRTX
190 hedge funds and large institutions have $454M invested in Heron Therapeutics in 2024 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 67 increasing their positions, 39 reducing their positions, and 15 closing their positions.
200% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 15
72% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 39
37% more capital invested
Capital invested by funds: $331M → $454M (+$123M)
18% more funds holding
Funds holding: 161 → 190 (+29)
6.65% more ownership
Funds ownership: 79.39% → 86.04% (+6.7%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
32% less call options, than puts
Call options by funds: $532K | Put options by funds: $781K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$8.73M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$3.89M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.59M |
| 5 |
BlackRock
New York
|
+$3.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$11.1M |
| 2 |
Millennium Management
New York
|
-$5.32M |
| 3 |
CC
Clearline Capital
New York
|
-$3.94M |
| 4 |
Renaissance Technologies
New York
|
-$1.27M |
| 5 |
MAM
Monaco Asset Management
Monaco
|
-$922K |
HRTX Hedge Fund Activity: Q2 2024 in Review
190 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2024, worth a combined $454M — up 37% from $331M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new HRTX positions and 15 closed out — a net gain of 30 holders — while 67 added to existing stakes and 39 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $14.4M. The largest seller was OrbiMed, cutting an estimated $11.1M.
- 190 institutional investors held Heron Therapeutics (HRTX) as of Q2 2024, up from 161 in Q1 2024.
- Funds reported $454M of Heron Therapeutics stock for Q2 2024, up 37% quarter-over-quarter.
- 45 funds opened new Heron Therapeutics positions in Q2 2024 and 15 closed out, a net change of +30 holders.
- The largest Heron Therapeutics buyer in Q2 2024 was Adage Capital Partners, an estimated $14.4M added.
- The largest Heron Therapeutics seller in Q2 2024 was OrbiMed, an estimated $11.1M sold.
Based on aggregated 13F filings for Q2 2024.